These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 17243166)

  • 21. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis.
    Sharp R; Recio JA; Jhappan C; Otsuka T; Liu S; Yu Y; Liu W; Anver M; Navid F; Helman LJ; DePinho RA; Merlino G
    Nat Med; 2002 Nov; 8(11):1276-80. PubMed ID: 12368906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
    Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
    Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis.
    Tang S; Luo H; Yu J; Yang D; Shu J
    Chin Med J (Engl); 2003 Jul; 116(7):1083-7. PubMed ID: 12890389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression.
    Chen Y; Takita J; Mizuguchi M; Tanaka K; Ida K; Koh K; Igarashi T; Hanada R; Tanaka Y; Park MJ; Hayashi Y
    Genes Chromosomes Cancer; 2007 Apr; 46(4):348-58. PubMed ID: 17243166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting MET Receptor in Rhabdomyosarcoma: Rationale and Progress.
    Szewczyk B; Skrzypek K; Majka M
    Curr Drug Targets; 2017; 18(1):98-107. PubMed ID: 26674534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rhabdomyosarcomagenesis-Novel pathway found.
    Asakura A; Rudnicki MA
    Cancer Cell; 2003 Dec; 4(6):421-2. PubMed ID: 14706332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A mouse model of activating Met mutations.
    Graveel CR; London CA; Vande Woude GF
    Cell Cycle; 2005 Apr; 4(4):518-20. PubMed ID: 15738649
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.